Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 3;6(3):976–992. doi: 10.1182/bloodadvances.2021005725

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 2. — Expert-independent classification of the CLL, MCL, and CD10⁺ DLBCL validation cohorts. Out of the total possible 36 2-dimensional CCA-based projections, the 8 projections that include CLL (A), MCL (B), and CD10⁺ DLBCL (C) are shown only. The X- and Y-axes of each plot represent CA1 and CA2. CA1 is the projection that captures most of the information for maximum separation between 2 B-CLPD entities; CA2 is the projection that provides the second-greatest amount of independent information for separation. Numbers in the top part of each plot represent the x fold SD of the immunophenotype shown. Numbers in brackets denote the relative contribution of markers to CA1 and CA2, respectively (see supplemental Table 4 for a full list of markers and coefficients). Each dot represents the median of 1 case from the validation cohort. (A) Cases included into all 8 representations for CLL are shown in green (n = 112); cases not included into all 8 plots for this leukemia are shown in red (“not classified”, n = 13). These 13 cases did not meet all 8 decision criteria for any other lymphoma. (B) Cases included into all 8 representations for MCL are shown in blue (n = 41); cases not included into all 8 plots for that lymphoma are shown in red (n = 14). Thereof, 13 cases did not meet all 8 decision criteria for any other lymphoma, and 1 MCL was misclassified as LPL (data not shown).

Figure 2. — Expert-independent classification of the CLL, MCL, and CD10⁺ DLBCL validation cohorts. Out of the total possible 36 2-dimensional CCA-based projections, the 8 projections that include CLL (A), MCL (B), and CD10⁺ DLBCL (C) are shown only. The X- and Y-axes of each plot represent CA1 and CA2. CA1 is the projection that captures most of the information for maximum separation between 2 B-CLPD entities; CA2 is the projection that provides the second-greatest amount of independent information for separation. Numbers in the top part of each plot represent the x fold SD of the immunophenotype shown. Numbers in brackets denote the relative contribution of markers to CA1 and CA2, respectively (see supplemental Table 4 for a full list of markers and coefficients). Each dot represents the median of 1 case from the validation cohort. (A) Cases included into all 8 representations for CLL are shown in green (n = 112); cases not included into all 8 plots for this leukemia are shown in red (“not classified”, n = 13). These 13 cases did not meet all 8 decision criteria for any other lymphoma. (B) Cases included into all 8 representations for MCL are shown in blue (n = 41); cases not included into all 8 plots for that lymphoma are shown in red (n = 14). Thereof, 13 cases did not meet all 8 decision criteria for any other lymphoma, and 1 MCL was misclassified as LPL (data not shown).